This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB08979/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/ontology/sukl/drug/
n10http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08979/identifier/drugbank/

Statements

Subject Item
n2:DB08979
rdf:type
n3:Drug
n3:description
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.
n3:group
approved
owl:sameAs
n12:DB08979
dcterms:title
Fenspiride
adms:identifier
n7:DB08979 n8:Fenspiride
n3:synonym
Eurespal
n3:synthesisReference
U.S. Patent 3,399,192.
n3:IUPAC-Name
n4:271B6189-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B618F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B618E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B618B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B618C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B618D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6187-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6185-363D-11E5-9242-09173F13E4C5 n4:271B6188-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6186-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:R03BX01 n10:R03DX03
n3:H-Bond-Acceptor-Count
n4:271B6195-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6196-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6190-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6191-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6193-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6192-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6194-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
5053-06-5
n3:Bioavailability
n4:271B619B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B619D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B619E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B619F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B619A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6199-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B619C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B618A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6197-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6198-363D-11E5-9242-09173F13E4C5